There is no universal time limit on hormone replacement therapy. How long you can safely take it depends on why you’re using it, what type you’re taking, when you started, and your individual risk factors. Some people use HRT for a few years to manage menopause symptoms, while others stay on it for a decade or longer. In certain cases, it’s taken for life.
The General Window for Menopause Symptoms
Most women start HRT to relieve hot flashes, night sweats, and other vasomotor symptoms of menopause. For women under 60 who begin within 10 years of their last period, the benefit-to-risk ratio is favorable. That 10-year window is a key threshold in current guidelines from the North American Menopause Society (NAMS).
Starting HRT more than 10 years after menopause onset, or after age 60, shifts the balance. The absolute risks of heart disease, stroke, blood clots, and dementia rise in that group. This doesn’t mean HRT is automatically off the table for older women, but the conversation with a prescriber becomes more nuanced.
There’s no fixed rule that says you must stop at five years, despite what you may have heard. NAMS supports longer durations for women who still have persistent symptoms, as long as there’s a periodic review of whether the benefits still outweigh the risks. Many women find that their symptoms last well beyond five years. Some experience hot flashes for a decade or more, and for them, continued use is reasonable.
Premature Menopause Changes the Timeline
If your ovaries stopped working before age 40, a condition called primary ovarian insufficiency, the guidelines are different. The American College of Obstetricians and Gynecologists recommends continuing HRT until at least age 50 or 51, the average age of natural menopause. This isn’t optional symptom management. It’s replacing hormones your body would normally still be producing, which protects your bones, heart, and brain during years when you’d otherwise have none of that hormonal support.
How Breast Cancer Risk Changes Over Time
Breast cancer risk is the concern most people have about long-term use, and the numbers are more modest than many expect. For combination therapy (estrogen plus a progestogen) started at age 50, five years of use adds about 0.6% to your cumulative breast cancer risk calculated through age 79. Ten years adds about 1.6%. To put that in context, the baseline risk with no HRT at all is roughly 6.1%, and ten years of combination therapy brings it to about 7.7%.
Estrogen-only therapy, used by women who’ve had a hysterectomy, carries even less additional risk. Five years of use starting at age 50 adds just 0.2%, and even 15 years adds under 1%. These are population-level averages, and your personal risk depends on family history, body weight, alcohol intake, and other factors. But the absolute numbers help explain why many specialists are comfortable with extended use when symptoms warrant it.
Endometrial Cancer and Why the Type Matters
Estrogen taken alone, without a progestogen, dramatically increases endometrial cancer risk in women who still have a uterus. Five or more years of unopposed estrogen can raise that risk tenfold to thirtyfold. This is why combination therapy exists: adding a progestogen not only eliminates that excess risk but actually reduces endometrial cancer risk by about 35% compared to using no hormones at all. If you have a uterus, you’ll always be prescribed a progestogen alongside estrogen, regardless of how long you stay on HRT.
Bone Protection Lasts Beyond Treatment
HRT is one of the most effective ways to prevent the bone loss that accelerates after menopause. A study following 347 women for up to 15 years after they stopped HRT found that even two to three years of early postmenopausal use left bones measurably stronger (more than 5% higher bone density) years later compared to women who never took it. Once you stop, bone loss resumes at normal postmenopausal rates rather than accelerating. So even a relatively short course of HRT provides lasting skeletal benefit, though the protection gradually diminishes over time.
Vaginal Estrogen Plays by Different Rules
Low-dose vaginal estrogen, used for vaginal dryness, painful sex, and urinary symptoms, is a separate category from systemic HRT. Because it acts locally and newer formulations (rings, tablets, inserts) produce minimal increases in blood estrogen levels, it’s considered safe for extended use. Trials lasting up to a year show no clear evidence of endometrial stimulation, and the tiny amount absorbed into the bloodstream is far below what systemic therapy delivers. Most specialists treat vaginal estrogen as something you can continue indefinitely, since the symptoms it treats tend to worsen with age rather than resolve on their own.
Gender-Affirming Hormone Therapy
For transgender and gender diverse adults, hormone therapy serves a fundamentally different purpose and follows a different timeline. Masculinizing hormone therapy (testosterone) is typically continued for life to maintain the physical changes it produces. Whether feminizing therapy (estrogen) needs dose adjustments in older age hasn’t been established yet, but it’s also generally lifelong.
Long-term monitoring becomes increasingly important as these individuals age. Screening for cardiovascular disease, bone density loss, and certain cancers should follow the same principles as for anyone on long-term hormones, with some additional considerations. Bone density screening is particularly important for anyone who has had their gonads removed, especially if hormone therapy is interrupted. Breast cancer screening for transfeminine adults on estrogen typically begins after at least five years of use, starting between ages 40 and 50 depending on regional guidelines.
What Annual Reviews Look Like
Regardless of how long you stay on HRT, you should have at least one review per year. These are straightforward: a blood pressure and weight check, a conversation about any side effects, and a discussion of whether your reasons for taking HRT still apply and whether your risk profile has changed. You’ll also be encouraged to stay current on mammograms and cervical screening as appropriate for your age. The review isn’t a hurdle to clear. It’s a check-in to make sure the therapy is still working for you.
Stopping HRT: Tapering vs. Going Cold Turkey
When you do decide to stop, the question of how to stop doesn’t have a clear answer. No evidence-based guidelines exist for the best approach. Some women stop abruptly, others taper their dose over weeks or months. When participants in the Women’s Health Initiative trial stopped suddenly, 55.5% of those who’d had hot flashes before starting therapy experienced them again, compared to 21.3% on placebo. About 7.6% restarted therapy, mostly because of returning symptoms.
Tapering is associated with fewer symptoms after discontinuation, but interestingly, women who taper are about twice as likely to eventually restart HRT compared to those who stop abruptly. This may be because gradual dose reduction makes women more aware of creeping symptoms, prompting them to resume treatment. Neither approach is clearly superior, and the best strategy depends on how your body responds.
Some women try stopping and find their symptoms return with enough intensity to affect daily life. Going back on HRT is a perfectly valid choice at that point. The decision to continue isn’t a failure to quit. It’s a recognition that, for some people, the symptoms persist long enough that ongoing treatment remains the better option.